Gene · 4016
Papers1,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring diagnostic biomarkers of type 2 cardio-renal syndrome based on secreted proteins and bioinformatics analysis. | Sci Rep | 2024 | 39427047 | PubTator, text mining | PubMed |
| Lipoprotein transport system Lol may be a selective target for Gram-negative bacteria. | Front Cell Infect Microbiol | 2024 | 39421643 | PubTator, text mining | PubMed |
| The epigenetic-modified downregulation of LOXL1 protein mediates EMT in bladder epithelial cells exposed to benzo[a]pyrene and its metabolite BPDE. | Int Immunopharmacol | 2024 | 39340995 | PubTator, text mining | PubMed |
| Identification and validation of potential prognostic biomarkers in glioblastoma via the mesenchymal stem cell infiltration level. | Front Oncol | 2024 | 39286023 | PubTator, text mining | PubMed |
| Key Cell-in-Cell Related Genes are Identified by Bioinformatics and Experiments in Glioblastoma. | Cancer Manag Res | 2024 | 39253064 | PubTator, text mining | PubMed |
| Matrisome proteomics reveals novel mediators of muscle remodeling with aerobic exercise training. | Matrix Biol Plus | 2024 | 39220302 | PubTator, text mining | PubMed |
| Minimal phenotypes in transgenic mice with the human LOXL1/LOXL1-AS1 locus associated with exfoliation glaucoma. | Vision Res | 2024 | 39151208 | PubTator, text mining | PubMed |
| A comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells. | Front Oncol | 2024 | 39136001 | PubTator, text mining | PubMed |
| [Retracted] LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑HSPA9. | Oncol Rep | 2024 | 39129318 | PubTator, text mining | PubMed |
| A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. | Cell Chem Biol | 2024 | 39043186 | PubTator, text mining | PubMed |
| Lysyl oxidase-like 1 predicts the prognosis of patients with primary glioblastoma and promotes tumor invasion via EMT pathway. | PeerJ | 2024 | 38978755 | PubTator, text mining | PubMed |
| Retraction Note: Differential Expression of LOXL1-AS1 in Coronary Heart Disease and Its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis. | Cardiovasc Drugs Ther | 2024 | 38954174 | PubTator, text mining | PubMed |
| Adding Genetics to the Risk Factors Model Improved Accuracy for Detecting Visual Field Progression in Newly Diagnosed Exfoliation Glaucoma Patients. | Biomedicines | 2024 | 38927432 | PubTator, text mining | PubMed |
| Genetic susceptibility to optic neuropathy in patients with alcohol use disorder. | J Transl Med | 2024 | 38796496 | PubTator, text mining | PubMed |
| Lack of evidence for GWAS signals of exfoliation glaucoma working via monogenic loss-of-function mutation in the nearest gene. | Hum Mol Genet | 2024 | 38770563 | PubTator, text mining | PubMed |
| Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review. | Transl Cancer Res | 2024 | 38737681 | PubTator, text mining | PubMed |
| LOXL1-AS1 contributes to metastasis in sonic-hedgehog medulloblastoma by promoting cancer stem-like phenotypes. | J Exp Clin Cancer Res | 2024 | 38689348 | PubTator, text mining | PubMed |
| Identification of hub genes and key pathways in spinal cord injury via bioinformatics analysis. | Cell Mol Biol (Noisy-le-grand) | 2024 | 38650155 | PubTator, text mining | PubMed |
| Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression. | Life Sci Alliance | 2024 | 38565287 | PubTator, text mining | PubMed |
| Genetic Associations of Primary Angle-Closure Disease: A Systematic Review and Meta-Analysis. | JAMA Ophthalmol | 2024 | 38546604 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4016/papers?page=5